Atlantic Union Bankshares Corp Purchases Shares of 4,099 Bio-Rad Laboratories, Inc. $BIO

Atlantic Union Bankshares Corp acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,099 shares of the medical research company’s stock, valued at approximately $1,149,000.

Other large investors also recently made changes to their positions in the company. Farther Finance Advisors LLC raised its stake in Bio-Rad Laboratories by 52.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock worth $29,000 after buying an additional 36 shares during the period. UMB Bank n.a. grew its position in Bio-Rad Laboratories by 24.0% in the 3rd quarter. UMB Bank n.a. now owns 207 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 40 shares during the period. Frank Rimerman Advisors LLC increased its stake in Bio-Rad Laboratories by 3.0% during the 2nd quarter. Frank Rimerman Advisors LLC now owns 1,806 shares of the medical research company’s stock valued at $436,000 after purchasing an additional 53 shares in the last quarter. Oppenheimer Asset Management Inc. raised its holdings in Bio-Rad Laboratories by 1.9% during the second quarter. Oppenheimer Asset Management Inc. now owns 2,871 shares of the medical research company’s stock worth $693,000 after buying an additional 54 shares during the last quarter. Finally, M&T Bank Corp lifted its stake in shares of Bio-Rad Laboratories by 3.7% in the second quarter. M&T Bank Corp now owns 1,855 shares of the medical research company’s stock valued at $447,000 after buying an additional 66 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on BIO. Citigroup upped their target price on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research note on Monday, December 29th. Wall Street Zen upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Finally, Wells Fargo & Company upped their price target on Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Bio-Rad Laboratories currently has an average rating of “Hold” and a consensus price target of $358.50.

Bio-Rad Laboratories Price Performance

Bio-Rad Laboratories stock opened at $306.53 on Thursday. Bio-Rad Laboratories, Inc. has a 52 week low of $211.43 and a 52 week high of $351.02. The company’s 50 day moving average price is $309.69 and its two-hundred day moving average price is $299.35. The stock has a market cap of $8.27 billion, a P/E ratio of -12.61 and a beta of 1.18. The company has a quick ratio of 3.94, a current ratio of 5.44 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.